Point72 Hong Kong LTD Axogen, Inc. Transaction History

Point72 Hong Kong LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$6.99 - $10.0 $845 - $1,210	121 Added 7.96%	1,641 $13,000
Q1 2022 May 16, 2022	BUY	$7.26 - $10.7 $10,265 - $15,129	1,414 Added 1333.96%	1,520 $12,000
Q4 2021 Feb 14, 2022	SELL	$8.8 - $16.0 $9,407 - $17,104	-1,069 Reduced 90.98%	106 $1,000
Q3 2021 Nov 15, 2021	BUY	$15.23 - $21.72 $17,895 - $25,521	1,175 New	1,175 $19,000
Q2 2021 Aug 16, 2021	SELL	$17.8 - $23.5 $4,966 - $6,556	-279 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$17.18 - $22.6 $4,793 - $6,305	279 New	279 $6,000
Q4 2020 Feb 16, 2021	SELL	$11.5 - $17.96 $10,235 - $15,984	-890 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.62 - $13.12 $9,451 - $11,676	890 New	890 $10,000
Q4 2019 Feb 14, 2020	SELL	$11.18 - $18.6 $2,616 - $4,352	-234 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$12.09 - $20.46 $1,620 - $2,741	134 Added 134.0%	234 $3,000
Q2 2019 Aug 14, 2019	BUY	$18.5 - $25.47 $333 - $458	18 Added 21.95%	100 $2,000
Q1 2019 May 15, 2019	BUY	$14.62 - $22.13 $1,198 - $1,814	82 New	82 $2,000

162

36.6M

230K

400

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $661M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.